With lots of ASX shares to choose from on the Australian market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are outlined below. Here's why they are bullish on them:
Image source: Getty Images
ANZ Group Holdings Ltd (ASX: ANZ)
According to a note out of Citi, its analysts have retained their buy rating and $39.25 price target on this banking giant's shares. Citi highlights that Judo Capital Holdings Ltd (ASX: JDO) recently downgraded its earnings guidance due to three specific exposures. The broker believes these exposures are a credit risk problem and not signs of a systemic issue. As a result, it isn't worried about ANZ at this stage. However, it concedes that the economy is in a challenging place and there are macro headwinds that the big banks could face. Nevertheless, the broker likes ANZ due to its exposure to business banking, which it prefers to retail banking at present. The ANZ share price is trading at $35.11 on Monday.
Neuren Pharmaceuticals Ltd (ASX: NEU)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this biotechnology company's shares with an improved price target of $23.50. This follows news that European regulators have reversed a negative recommendation on its Daybue product, which makes its approval quite likely now. Outside this, the broker estimates that the market is giving no value to Neuren's NNZ-2591 product, which is under development. This could be a big mistake given how it estimates the product could be a multi-billion-dollar value asset if it succeeds in its Phase 3 trial. Trial results for NNZ-2591 are expected towards the end of 2027. The Neuren Pharmaceuticals share price is fetching $15.63 at the time of writing.
Qualitas Ltd (ASX: QAL)
Analysts at Macquarie have retained their outperform rating on this alternative asset manager's shares with a trimmed price target of $3.95. According to the note, the broker was pleased to see Qualitas upgrade its margin guidance for long-term funds management EBITDA. It notes that this is being driven by benefits from an AI-enabled platform that should streamline the investment process. In addition, it has been pleased to see the company continues its long run of growing funds under management quicker than peers. It expects this to underpin strong earnings per share growth through to at least FY 2028. The Qualitas share price is trading at $3.01 this morning.
